Amniotics AB (publ) (AMNI.ST)
SEK 0.01
(5.88%)
SEK 0.01
(5.88%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -1.93 Million SEK | -7.64% |
| 2022 | -1.79 Million SEK | 16.72% |
| 2021 | -2.15 Million SEK | -35.73% |
| 2020 | -1.58 Million SEK | -463.56% |
| 2019 | -281.47 Thousand SEK | -28147800.0% |
| 2018 | -1.00 SEK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 Q3 | -471 Thousand SEK | 6.18% |
| 2023 Q4 | -471 Thousand SEK | 0.0% |
| 2023 Q1 | -486 Thousand SEK | -3.85% |
| 2023 Q2 | -502 Thousand SEK | -3.29% |
| 2023 FY | -1.93 Million SEK | -7.64% |
| 2022 Q3 | -447 Thousand SEK | 0.22% |
| 2022 Q4 | -468 Thousand SEK | -4.7% |
| 2022 Q2 | -448 Thousand SEK | -4.43% |
| 2022 Q1 | -429 Thousand SEK | 50.4% |
| 2022 FY | -1.79 Million SEK | 16.72% |
| 2021 Q1 | -426 Thousand SEK | 0.0% |
| 2021 Q4 | -865 Thousand SEK | -99.77% |
| 2021 Q3 | -433 Thousand SEK | -1.17% |
| 2021 Q2 | -428 Thousand SEK | -0.47% |
| 2021 FY | -2.15 Million SEK | -35.73% |
| 2020 FY | -1.58 Million SEK | -463.56% |
| 2020 Q4 | - SEK | 0.0% |
| 2020 Q3 | - SEK | 0.0% |
| 2020 Q2 | - SEK | 0.0% |
| 2020 Q1 | - SEK | 0.0% |
| 2019 FY | -281.47 Thousand SEK | -28147800.0% |
| 2018 FY | -1.00 SEK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -160.68 Million SEK | 98.799% |
| Ziccum AB (publ) | -23.28 Million SEK | 91.712% |
| Modus Therapeutics Holding AB (publ) | - SEK | Infinity% |
| BioArctic AB (publ) | 346.31 Million SEK | 100.557% |
| Sprint Bioscience AB (publ) | 41.78 Million SEK | 104.619% |
| Mendus AB (publ) | 28.48 Million SEK | 106.775% |
| Genovis AB (publ.) | 54 Million SEK | 103.574% |
| Intervacc AB (publ) | -13.79 Million SEK | 86.008% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 2.17 Million SEK | 188.899% |
| Active Biotech AB (publ) | -1.67 Million SEK | -15.224% |
| Magle Chemoswed Holding AB (publ) | 9.96 Million SEK | 119.372% |
| Bio-Works Technologies AB (publ) | 26.82 Million SEK | 107.196% |
| Aptahem AB (publ) | 2.63 Million SEK | 173.366% |
| Vicore Pharma Holding AB (publ) | -3.42 Million SEK | 43.584% |
| Kancera AB (publ) | -1.96 Million SEK | 1.781% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | 2606.494% |
| Fluicell AB (publ) | 1.73 Million SEK | 211.047% |
| Saniona AB (publ) | 11.78 Million SEK | 116.382% |
| Lipigon Pharmaceuticals AB (publ) | -5.11 Million SEK | 62.283% |
| Biovica International AB (publ) | 6.87 Million SEK | 128.065% |
| Spago Nanomedical AB (publ) | -23.28 Million SEK | 91.711% |
| AcouSort AB (publ) | 8.38 Million SEK | 123.006% |
| Xintela AB (publ) | 78 Thousand SEK | 2574.359% |
| Abliva AB (publ) | -35.66 Million SEK | 94.588% |
| Egetis Therapeutics AB (publ) | -146.9 Million SEK | 98.686% |
| Karolinska Development AB (publ) | 2.8 Million SEK | 168.757% |
| OncoZenge AB (publ) | 3000.00 SEK | 64433.333% |
| 2cureX AB (publ) | -37.48 Million SEK | 94.852% |
| CombiGene AB (publ) | -21.29 Million SEK | 90.935% |
| Asarina Pharma AB (publ) | -423 Thousand SEK | -356.265% |
| Calliditas Therapeutics AB (publ) | 1.12 Billion SEK | 100.171% |
| Camurus AB (publ) | 1.58 Billion SEK | 100.122% |
| Corline Biomedical AB | 28.38 Million SEK | 106.801% |
| IRLAB Therapeutics AB (publ) | -122.73 Million SEK | 98.427% |
| Isofol Medical AB (publ) | -34.41 Million SEK | 94.392% |
| I-Tech AB | 27.56 Million SEK | 107.001% |
| Hansa Biopharma AB (publ) | 70.95 Million SEK | 102.72% |
| Cyxone AB (publ) | 2.61 Million SEK | 173.918% |
| ExpreS2ion Biotech Holding AB (publ) | 3.4 Million SEK | 156.715% |
| Biosergen AB | -456 Thousand SEK | -323.246% |
| Cantargia AB (publ) | -3.45 Million SEK | 44.074% |
| NextCell Pharma AB | -43.74 Million SEK | 95.588% |
| Xspray Pharma AB (publ) | -9.19 Million SEK | 79.008% |
| Elicera Therapeutics AB (publ) | 11.21 Million SEK | 117.204% |
| Nanologica AB (publ) | -76 Thousand SEK | -2439.474% |
| SynAct Pharma AB | -778 Thousand SEK | -148.072% |
| Annexin Pharmaceuticals AB (publ) | -193 Thousand SEK | -900.0% |
| Stayble Therapeutics AB (publ) | - SEK | Infinity% |
| LIDDS AB (publ) | -12.92 Million SEK | 85.064% |
| Lipum AB (publ) | 53 Thousand SEK | 3741.509% |
| BioInvent International AB (publ) | 71.46 Million SEK | 102.701% |
| Alzinova AB (publ) | 19.87 Million SEK | 109.711% |
| Oncopeptides AB (publ) | 36.29 Million SEK | 105.317% |
| Pila Pharma AB (publ) | 1.46 Million SEK | 231.919% |
| Guard Therapeutics International AB (publ) | -15 Thousand SEK | -12766.667% |
| Scandinavian ChemoTech AB (publ) | 1.65 Million SEK | 216.405% |
| Simris Alg AB (publ) | 2 Million SEK | 196.163% |
| Diamyd Medical AB (publ) | -3.58 Million SEK | 46.089% |
| Xbrane Biopharma AB (publ) | 35.38 Million SEK | 105.454% |
| Ascelia Pharma AB (publ) | -1.04 Million SEK | -83.985% |
| Diagonal Bio AB (publ) | 3.13 Million SEK | 161.602% |